Lipocine earnings release, May 7, 2026

Lipocine Inc. (LPCN) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Lipocine

Inc.

Lipocine

Announces Financial Results for the

First

Quarter Ended March 31, 2026

SALT

LAKE CITY, May 07, 2026 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the first quarter ended March 31, 2026 and provided a corporate update.

Neuroactive

Steroids (NAS)

LPCN

1154 for Postpartum Depression (“PPD”)

TLANDO®

First

Quarter Ended March 31, 2026, Financial Results

As of March 31, 2026, Lipocine had $24.7 million of unrestricted cash, cash equivalents and marketable investment securities compared to

$14.9 million at December 31, 2025.

Lipocine reported a net loss of $3.7 million, or ($0.52) per diluted share, for the quarter ended March 31, 2026, compared with a net loss of

$1.9 million, or ($0.35) per diluted share, for the quarter ended March 31, 2025.

The company recognized royalty revenue from TLANDO sales of $119,000 during the quarter ended March 31, 2026, compared to royalty revenue of $94,000 during the quarter ended March 31, 2025.

Research and development expenses were $2.8 million and $1.1 million, respectively, for the quarters ended March 31, 2026 and 2025. The increase in research and development expenses was mainly the result of an increase in costs related to our LPCN 1154 clinical study in 2026.

General and administrative expenses were $1.2 million and $1.1 million, respectively, for the quarters ended March 31, 2026 and 2025. The increase in general and administrative expenses was primarily a result of an increase in various professional and consulting fees.

For further details on Lipocine’s financial results for the quarter ended March 31, 2026, refer to Form 10-Q filed with the SEC.

About

Lipocine

Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery.

Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.

Lipocine’s development pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder,

LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted for the management of symptoms associated with liver cirrhosis, and LPCN 1107 our candidate for prevention of preterm birth. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended March 31, — (Unaudited)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Revenues:Royalty revenue119,39793,864
Revenues:Total revenues119,39793,864
Operating expenses:Research and development2,764,3941,061,571
Operating expenses:General and administrative1,204,4671,122,477
Operating expenses:Total operating expenses3,968,8612,184,048
Operating expenses:Operating loss-3,849,464-2,090,184
Other income:Interest and investment income177,570225,511
Other income:Total other income177,570225,511
Other income:Loss before income tax expense-3,671,894-1,864,673
Other income:Income tax expense-200
Other income:Net loss attributable to common shareholders Net loss attributable to common shareholders-3,671,894-1,864,873
Other income:Basic loss per share attributable to common stock-0.54-0.35
Other income:Weighted average common shares outstanding, basic6,795,0025,348,557
Other income:Diluted loss per share attributable to common stock-0.54-0.35
Other income:Weighted average common shares outstanding, diluted6,795,0025,348,557
Comprehensive loss:Net loss-3,671,894-1,864,873
Comprehensive loss:Net unrealized loss on marketable investment securities-11,639-3,617
Comprehensive loss:Comprehensive loss-3,683,533-1,868,490

Balance Sheet

December 31, — (Unaudited)

March 31, – 2026December 31, – 2025
Current assets:Cash and cash equivalents5,015,6085,205,842
Current assets:Marketable investment securities19,713,4639,724,545
Current assets:Accrued interest income111,41114,189
Current assets:License fee and royalties receivable119,3971,145,390
Current assets:Prepaid and other current assets285,055787,600
Current assets:Total current assets25,244,93416,877,566
Current assets:Property and equipment, net of accumulated depreciation of $1,298,893 and $1,284,079 respectively89,479104,293
Current assets:Other assets23,75323,753
Current assets:Total assets25,358,16617,005,612
Current liabilities:Accounts payable1,562,728971,822
Current liabilities:Accrued expenses645,1151,236,374
Current liabilities:Deferred revenue320,000320,000
Current liabilities:Total current liabilities2,527,8432,528,196
Current liabilities:Total liabilities2,527,8432,528,196
Stockholders’ equity:Common stock, par value $0.0001 per share, 75,000,000 shares authorized; 7,475,451 and 6,158,779 issued and 7,475,115 and 6,158,443 outstanding, respectively9,0768,944
Stockholders’ equity:Additional paid-in capital235,937,414223,901,106
Stockholders’ equity:Treasury stock at cost, 336 shares-40,712-40,712
Stockholders’ equity:Accumulated other comprehensive income-7,1944,445
Stockholders’ equity:Accumulated deficit-213,068,261-209,396,367
Stockholders’ equity:Total stockholders’ equity22,830,32314,477,416
Stockholders’ equity:Total liabilities and stockholders’ equity25,358,16617,005,612
Full release

This release contains “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities

Litigation Reform Act of 1995 and include statements that are not historical facts regarding the potential uses and benefits of products and product candidates, the commercial potential for product candidates, the timing of regulatory reviews and approvals and related procedures, and potential strategic opportunities. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates or we may decide to allocate our available capital to other product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our assets, safety and efficacy studies, including those relating to LPCN 1154, may not be successful or may not provide results that would support the submission of a NDA, the FDA may not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, patient acceptance of Lipocine’s products, the manufacturing and commercialization of Lipocine’s products, and other risks detailed in Lipocine’s filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov.

Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

SOURCE

Lipocine Inc.

For further information:

Krista

Fogarty

Phone:

(801) 994-7383 kf@lipocine.com

Investors:

PJ

Kelleher

Phone:

(617) 430-7579 pkelleher@lifesciadvisors.com

LIPOCINE

INC. AND SUBSIDIARIES

Condensed

Consolidated Balance Sheets

(Unaudited)

LIPOCINE

INC. AND SUBSIDIARIES

Condensed

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Lipocine earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.